Conditional Cytotoxic Anti-HIV Gene Therapy for Selectable Cell Modification.

Area of Science:

• Virology
• Gene Therapy
• Immunology

Background:

• Gene therapy offers potential HIV cures but struggles with sufficient modified cell recovery.
• Effective anti-HIV strategies require robust methods for selecting and retaining modified cells.

Purpose of the Study:

• To develop a gene therapy method for selecting modified cells and eliminating HIV-infected cells.
• To evaluate the efficacy of a conditional HIV vector expressing a potent herpes simplex virus thymidine kinase (TK) mutant (SR39) for anti-HIV gene therapy.

Main Methods:

• A conditional HIV vector (pNL-GFPRRESA) was engineered to express green fluorescent protein (GFP) and the TK-SR39 gene, activated by HIV Tat protein.
• Cells were marked with GFP via transient Tat expression, enabling selection of modified cells.
• The potency of TK-SR39 was compared to wild-type TK (TK-WT) in eliminating infected cells with ganciclovir (GCV).

Main Results:

• TK-SR39 demonstrated higher potency than TK-WT in eliminating infected cells at lower GCV concentrations.
• The selection strategy effectively enriched for modified cells, leading to more potent suppression of HIV replication.
• GCV treatment suppressed HIV infection, viral production, and cytopathic effects in selected Jurkat cells.

Conclusions:

• The combination of TK-SR39 in a conditional HIV vector provides a promising, safe, and effective strategy for anti-HIV gene therapy.
• This approach addresses the challenge of insufficient modified cell numbers in gene therapy for HIV.
• The study offers proof of principle for a novel therapeutic avenue against HIV infection.